MRI interstitial 125I seed implantation treatment for oral and maxillofacial adenogenic malignant tumor
10.3760/cma.j.issn.1002-0098.2016.06.006
- VernacularTitle:MRI导航下125I治疗颌面部腺源性恶性肿瘤效果初探
- Author:
Rui LI
1
;
Kun FU
;
Ning GAO
;
Wenlu LI
;
Xi WANG
;
Wei HE
Author Information
1. 450000,郑州大学第一附属医院口腔科
- Keywords:
Brachytherapy;
Adenocarcinoma;
Magnetic resonance imaging
- From:
Chinese Journal of Stomatology
2016;51(6):346-349
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the therapeutic efficacy of MRI guided interstitial 125I seed implantation in the treatment of oral and maxillofacial adenogenic malignant tumor Methods A total of 39 patients with oral and maxillofacial adenogenic malignant tumors received interstitial 125I implantation treatment one week postoperatively.Before implantation,MRI scanning was performed and implantation plan of 125I was designed with the aid of treating plan system.During the implantation,positioning pin was firstly implanted and then its position and direction were adjusted according to navigation.Next,125I was delivered into the target region.Real-time assessment was required to find if the sites of implantation corresponded with that of preoperative design.One week and two months after implantation,CT scanning and dosimetric analysis were performed.All the patients needed regular reexamination to observe if there was recurrence of tumor,lymphadenectasis in lymph draining region and distant metastasis.Results All the procedures of implantation were successful.Post-operative CT showed no seed migration and the location of implanted 125I was exact as designed.Among the 39 patients,7 cases suffered from tumor recurrence,with local control rate of 82％(32/29).One got pulmonary metastasis,and one had ipsilateral lymphadenectasis.No serious complications affected life quality,and no seeds migration was observed.Conclusions MRIguided implanting of 125I is an accurate way to treat oral and maxillofacial adenogenic malignant tumors,which could effectively decrease postoperative complications and tumor recurrence rate.
